Survival prognosis in advanced HER-2 negative gastric cancer treated with immunochemotherapy: A novel model

Table 5 Univariate and multivariate logistic regression for objective responds rates

Factors	Univariate		Multivariate
	HR (95%CI)	P value	HR (95%CI)	P value
Sex (female vs male)	0.62 (0.24-1.55)	0.302
Age (< 60 vs ≥ 60), years	0.74 (0.30-1.85)	0.520
BMI (≥ 25 vs < 25), kg/m2	0.77 (0.21-2.87)	0.701
CEA (< 3 vs ≥ 3), ng/mL	1.68 (0.67-4.20)	0.266
CA199 (< 37 vs ≥ 37), U/mL	1.31 (0.55-3.11)	0.543
ECOG PS (0 vs 1)	1.42 (0.54-3.74)	0.480
Staging (3 vs 4)	2.49 (1.15-5.40)	0.021	0.61 (0.15-2.45)	0.483
Differentiation (low vs medium-high)	0.08 (0.03-0.22)	< 0.001	0.11 (0.03-0.40)	< 0.001
Site (stomach vs gastric and esophageal binding)	1.14 (0.50-2.58)	0.760
Liver metastasis (no vs yes)	1.54 (0.59-3.98)	0.376
Peritoneal metastasis (no vs yes)	2.66 (1.13-6.26)	0.025	2.13 (0.54-8.44)	0.284
PD-L1 expression (CPS < 5 vs CPS ≥ 5)	0.07 (0.02-0.28)	< 0.001	0.13 (0.02-0.66)	0.014
MMR status (dMMR vs pMMR)	0.11 (0.04-0.31)	< 0.001	0.15 (0.04-0.61)	0.008
EBV status (infect vs no-infect)	0.27 (0.08-0.89)	0.031	0.32 (0.05-2.14)	0.242
CALLY index	0.86 (0.79-0.92)	< 0.001	0.88 (0.81-0.95)	0.002
NLR	1.16 (0.95-1.41)	0.144
SII	1.28 (1.10-1.48)	0.001	1.33 (1.05-1.69)	0.017

BMI: Body mass index; CEA: Carcinoembryonic antigen; CA199: Carbohydrate antigen 199; ECOG PS: Eastern Cooperative Oncology Group performance status; PD-L1: Programmed cell death ligand 1; CPS: Combined positive score; MMR: Mismatch repair; dMMR: Deficient mismatch repair; pMMR: Proficient mismatch repair; EBV: Epstein-Barr virus; CALLY: C-reactive protein-albumin-lymphocyte; NLR: Neutrophil-to-lymphocyte ratio; SII: Systemic immune inflammation.